Prurigo nodularis is a chronic inflammatory skin disorder marked by intensely itchy nodules, significantly impacting patients' quality of life. It accounts for approximately 0.19% prevalence in the United States. The growing focus on prurigo nodularis therapeutics is driven by unmet clinical needs, rising awareness, and increasing research investments. Several prurigo nodularis drug candidates are currently in clinical trials, with promising biologics targeting the IL-31 and IL-4/IL-13 pathways. The prurigo nodularis pipeline analysis by Expert Market Research highlights strong market potential, fueled by advancements in dermatological treatments and the development of targeted therapies expected to boost market growth in the coming years.
Amgen, Incyte Corporation, and others are major companies involved in the prurigo nodularis pipeline analysis.
Leading drugs currently in the pipeline include Povorcitinib, SHR-1819, Ruxolitinib Cream, and others.
The rising clinical trial activity, the development of biologics targeting IL-31 and IL-4/IL-13, and strong pharmaceutical R&D investments are positively influencing the prurigo nodularis pipeline landscape.
The Prurigo Nodularis Pipeline Analysis Report by Expert Market Research gives comprehensive insights into prurigo nodularis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for prurigo nodularis. The prurigo nodularis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The prurigo nodularis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with prurigo nodularis treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to prurigo nodularis.
Prurigo nodularis is a chronic inflammatory skin condition marked by intensely itchy nodules that often develop due to repeated scratching. It is associated with neuroimmune dysregulation, leading to skin thickening and scarring. The disease typically occurs in adults and is often linked to underlying conditions such as atopic dermatitis, liver or kidney disease, or psychological stress.
Prurigo nodularis treatment involves corticosteroids, antihistamines, immunomodulators, and emerging biologic therapies to reduce itch, inflammation, and nodule formation while improving patients’ quality of life. For instance, in August 2024, Galderma’s Nemluvio (nemolizumab) received U.S. FDA approval as the first monoclonal antibody targeting IL-31 signaling for prurigo nodularis, following positive phase III OLYMPIA trial results demonstrating rapid itch and lesion improvement.
According to studies, the global annual prevalence of prurigo nodularis ranges from 6.52 to 72 per 100,100 people. In the United States, the estimated prevalence is approximately 0.19%. In the United Kingdom, about 18,000 individuals are affected, while in Japan, the disease impacts an estimated 5.5 million adults. Patients often face a high disease burden with increased risks of psychiatric disorders and systemic illnesses.
This section of the report covers the analysis of prurigo nodularis drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III holds the largest share at 68.75% of the total prurigo nodularis clinical trials, indicating robust clinical advancement in prurigo nodularis drug development. Phase IV follows with 6.25%, while Phase I and Phase II each account for 12.5%.
The drug molecule categories covered under the prurigo nodularis pipeline analysis include monoclonal antibodies, small molecules, biologics, topical agents, and peptides. The prurigo nodularis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for prurigo nodularis.
Interleukin inhibitors are gaining prominence in the prurigo nodularis pipeline. For example, nemolizumab, an interleukin-31 receptor alpha antagonist, is in a phase 3 trial. It has shown significant improvement in itch reduction and lesion healing by targeting the neuroimmune pathway. This class of drugs offers a promising approach for treating moderate-to-severe prurigo nodularis.
The EMR report for the prurigo nodularis pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed prurigo nodularis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in prurigo nodularis clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for prurigo nodularis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of prurigo nodularis drug candidates.
Povorcitinib is currently being evaluated by Incyte Corporation in a Phase III trial (STOP-PN2) for prurigo nodularis (PN). Povorcitinib is an oral JAK1 inhibitor, showing promise in treating inflammatory skin diseases, including hidradenitis suppurativa and vitiligo. This randomized, double-blind, placebo-controlled study aims to assess the drug’s efficacy in reducing itch and skin lesions.
SHR-1819 is a novel monoclonal antibody developed by Guangdong Hengrui Pharmaceutical Co., Ltd, currently undergoing a Phase II/III trial to assess its efficacy and safety in adult patients with prurigo nodularis. The study is evaluating SHR-1819's ability to block hIL-4Rα, a key target in type 2 inflammatory pathways, aiming to reduce chronic itch and nodular lesions.
Ruxolitinib cream (Opzelura) is currently being evaluated in a Phase I study sponsored by Incyte Corporation to determine its safety and tolerability under maximal use conditions in adults with prurigo nodularis (PN). This selective JAK1/JAK2 inhibitor, already FDA-approved for vitiligo and atopic dermatitis, is being studied for its potential to address PN’s inflammatory skin lesions.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Prurigo Nodularis Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for prurigo nodularis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within prurigo nodularis pipeline insights.
Global Skin Antiseptic Products Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share